Achieve Life Sciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Achieve Life Sciences Inc.
- Former names
- Oncogenex Pharmaceuticals, INC. Sonus Pharmaceuticals Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2835 — In Vitro & In Vivo Diagnostic Substances
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ACHV
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000949858
- EIN
- 95-4343413
Board of directors
-
Aaron Royston · DirectorSince 2026
-
Andrew D. Goldberg · Director · CEO and PresidentSince 2026
-
Bridget A. Martell · DirectorSince 2023
-
Christopher Nathan Martin · DirectorSince 2026
-
Cindy Jacobs · Director · President & CMOSince 2023
-
Jeffrey S. Farrow · DirectorSince 2026
-
John Bencich · Director · CEOSince 2023
-
Kristen B. Slaoui · DirectorSince 2025
-
Lucian Iancovici · DirectorSince 2026
-
Nancy R. Phelan · DirectorSince 2025
-
Reid Alexander Waldman · DirectorSince 2026
-
Richard Alistair Stewart · Director · Chief Executive OfficerSince 2023
-
Stuart Duty · DirectorSince 2023
-
Thomas Braxton King · DirectorSince 2023
-
Thomas Sellig · DirectorSince 2023
-
Vaughn B. Himes · DirectorSince 2023
Chief executives
Andrew D. Goldberg
· CEO and President
Since April 2026
Richard Alistair Stewart
· Chief Executive Officer
Until April 2026
· Former
John Bencich
· CEO
Until April 2026
· Former
Director election results
Annual meeting of June 4, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.8%
-
86.4%
-
97.3%
-
97.5%
-
97.6%
-
98.4%
-
98.4%
Board connections
7 of this board's directors also sit on 12 other boards.
- via Bridget A. Martell
- via Aaron Royston
- via Lucian Iancovici
- via Bridget A. Martell
- via Christopher Nathan Martin
- via Stuart Duty
- via Stuart Duty
- via Stuart Duty
- via Christopher Nathan Martin
- via Lucian Iancovici
- via Andrew D. Goldberg
- via Reid Alexander Waldman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $175,177
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2026 | Richard Alistair Stewart Director | Open-market sale | −20,626 | $8.49 | $175,177 |
| Sep 18, 2025 | Oki Mark K Officer (Chief Financial Officer) | Option exercise | +168,000 | — | — |
| Sep 18, 2025 | Richard Alistair Stewart Director, Officer (Chief Executive Officer) | Option exercise | +297,500 | — | — |
| Sep 18, 2025 | Oki Mark K Officer (Chief Financial Officer) | Open-market sale | −50,060 | $2.92 | $146,175 |
| Sep 18, 2025 | Richard Alistair Stewart Director, Officer (Chief Executive Officer) | Open-market sale | −129,501 | $2.92 | $378,143 |
| Sep 4, 2025 | Wan Jerry Officer (Principal Accounting Officer) | Option exercise | +34,100 | — | — |
| Sep 4, 2025 | Thomas Braxton King Director | Option exercise | +455,000 | — | — |
| Sep 4, 2025 | Cindy Jacobs Officer (President & CMO) | Option exercise | +110,000 | — | — |
| Sep 4, 2025 | Xinos Jaime Officer (Chief Commercial Officer) | Option exercise | +69,000 | — | — |
| Sep 4, 2025 | Wan Jerry Officer (Principal Accounting Officer) | Open-market sale | −14,070 | $2.77 | $38,974 |
| Sep 4, 2025 | Thomas Braxton King Director | Open-market sale | −139,858 | $2.77 | $387,407 |
| Sep 4, 2025 | Cindy Jacobs Officer (President & CMO) | Open-market sale | −27,629 | $2.77 | $76,532 |
| Sep 4, 2025 | Xinos Jaime Officer (Chief Commercial Officer) | Open-market sale | −20,854 | $2.77 | $57,766 |
| Mar 17, 2025 | Oki Mark K Officer (Chief Financial Officer) | Open-market purchase | +10,000 | $2.89 | $28,900 |
| Mar 17, 2025 | Richard Alistair Stewart Director, Officer (Chieve Executive Officer) | Open-market purchase | +10,000 | $2.86 | $28,600 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.